Page 14 - Cipla

Nifty outlook & trading ideas by Vinay Rajani of HDFC Securities

Upside target for Nifty is seen at 14,300 odd levels, which happens to be the 138.2 per cent Fibonacci retracement of the downswing seen from 12,430 to 7,511

Cipla rallies 5% after settling litigation with Bristol Myers in US

Bristol Myers (Celgene) will provide Cipla with a license to sell generic volume-limited amounts of gRevlimid capsules in the US sometime after March 2022, subject to regulatory approval

Cipla settles blood cancer drug litigation with Bristol Myers in US

As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved

Chronic portfolio may help Cipla sustain growth outperformance in near term

Margin gains in the September quarter too are expected to continue

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Top headlines: Passenger vehicles sales dip; Finance Commission report out

The Bombay High Court refused to grant interim bail to TV journalist Arnab Goswami.

Demand for Covid-19 drug Remdesivir rising sharply in India, says Cipla

Cipla's version, Cipremi, was commercially launched in July and costs just above $50 per 100 mg vial

Top headlines: Free health checkup in cos soon; data breach at BigBasket

From new labour laws promising free annual health checkups to markets poised for fresh all-time highs as investors cheer Biden win, here are top headlines this morning

Cipla expects surge in demand for respiratory drugs, inhalers in winter

The firm enjoys a massive 68.7 per cent market share in the respiratory inhalation segment in India and has started working on aligning supplies so that there is no shortage of these critical medicine

Drugmaker Cipla eyes digital adoption to sustain growth through Covid-19

The drug firm has earmarked digital adoption and resilient operations as first of the key priorities for the coming quarters

Cipla posts net profit of Rs 665 cr in Q2, income from ops grows 15%

The company's prescription biz grew 14% YoY supported by continued traction in the Covid portfolio

USFDA approves Remdesivir as first Covid-19 therapy amid WHO reservations

Approval unlikely to increase prices immediately as Gilead has said licenses are royalty-free until the end of the health emergency

Chris Wood hikes allocation to Indian equities; raises stake in HDFC

Among Indian stocks, besides HDFC, Wood also holds Reliance Industries (RIL), Maruti Suzuki, SBI Life Insurance, DLF and Cipla

Pharma stocks gain; Cipla hits record high, Lupin nears 52-week high

In the past month, Cipla and Lupin outperformed the market by gaining 12 per cent each, against 8 per cent rise in Nifty Pharma index

Smaller pharma firms post faster domestic sales growth in September

Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth

Cipla up 5% on hope of healthy Q2 performance; rallies 56% in six months

The company is expected to report strong growth in the recently concluded quarter, driven by the portfolio of drugs it manufactures to combat Covid-19

Cipla shares gain 5% after USFDA okays capsules; m-cap rises by Rs 3,021 cr

The stock jumped 5.10 per cent to close at Rs 770.20 on the BSE. During the day, it rose by 5.97 per cent to Rs 776.60.

Cipla surges 5% on USFDA approval for dimethyl fumarate DR capsules

The drug, indicated for treatment of relapsing forms of multiple sclerosis, had annual US sales of US$3.8 billion as per IQVIA MAT July 2020.

Cipla gets final approval from USFDA for multiple sclerosis drug

Drug major Cipla on Friday said it has received final approval from the US health regulator for Dimethyl Fumarate capsules, indicated for the treatment of relapsing forms of multiple sclerosis. The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc's Tecfidera. Cipla has received final approval for its abbreviated new drug application (ANDA) for Dimethyl Fumarate DR (delayed release) capsules in the strengths of 120mg, 240mg and 120mg and 240mg from the United States Food and Drug Administration (USFDA), the company said in a regulatory filing. Quoting IQVIA (IMS Health) data, Cipla said Tecfidera had US sales of approximately USD 3.8 billion for the 12-month period ending July 2020. Shares of Cipla were trading 2.12 per cent higher at Rs 748.35 apiece on the BSE.

New Covid-19 drugs provide additional fuel as Cipla fires on all cylinders

Firm domestic sales and positive outlook in the US point to robust earnings